(Total Views: 524)
Posted On: 02/06/2020 10:24:48 AM
Post# of 1460
From IHUB falconer66a about 3-71. I may sell some today at $4 but will buy back quickly at like $3.80 or so,
Fletch
falconer66a Thursday, 02/06/20 09:58:08 AM
Re: None 0
Post # of 234288
Now, Finally, Anavex 3-71 Comes Into Play
Of all of the positive news in today’s announcement, I found the following (for me, at least) to be the most significant.
This morning’s announcement stated:
Quote:
ANAVEX®3-71 successfully completed IND-enabling toxicology studies and drug product manufacturing. ANAVEX®3-71 previously received Orphan Drug Designation from the U.S. FDA for Frontotemporal dementia (FTD). Initiation of the first Phase 1 clinical trial of ANAVEX®3-71 is expected in 2020. ANAVEX®3-71 has demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, inflammation, amyloid and tau pathologies.
As I’ve contended, the statement confirms that this new sigma-1 receptor agonist (Anavex 3-71) has been tested on transgenic mice with Alzheimer’s. In these little rodents it “has demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, inflammation, amyloid and tau pathologies.”
That pretty much covers Alzheimer’s treatment, does it not? I won’t go into it here, but there is abundant evidence from murine testing that Anavex 3-71 is even better able to moderate and normalize various homeostatic processes. Simply, it will most likely turn out to be even better than blarcamesine (Anavex 2-73). Glad to learn that human trials are forthcoming.
From my start with my AVXL holding, I’ve targeted 2023 as the year in which I will determine my investment success. So far, I will hold to it. By 2023, remarkable things will have happened with blarcamesine; most likely it will have gained sales approval somewhere. In 2023, the clinical results with Anavex 3-71 could appear from humans with Alzheimer’s and frontotemporal dementia (FTD). No reason whatsoever to anticipate results will be lacking. Just the opposite; probably far better than even blarcamesine.
https://investorshub.advfn.com/boards/read_ms...=153684550
Fletch
falconer66a Thursday, 02/06/20 09:58:08 AM
Re: None 0
Post # of 234288
Now, Finally, Anavex 3-71 Comes Into Play
Of all of the positive news in today’s announcement, I found the following (for me, at least) to be the most significant.
This morning’s announcement stated:
Quote:
ANAVEX®3-71 successfully completed IND-enabling toxicology studies and drug product manufacturing. ANAVEX®3-71 previously received Orphan Drug Designation from the U.S. FDA for Frontotemporal dementia (FTD). Initiation of the first Phase 1 clinical trial of ANAVEX®3-71 is expected in 2020. ANAVEX®3-71 has demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, inflammation, amyloid and tau pathologies.
As I’ve contended, the statement confirms that this new sigma-1 receptor agonist (Anavex 3-71) has been tested on transgenic mice with Alzheimer’s. In these little rodents it “has demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, inflammation, amyloid and tau pathologies.”
That pretty much covers Alzheimer’s treatment, does it not? I won’t go into it here, but there is abundant evidence from murine testing that Anavex 3-71 is even better able to moderate and normalize various homeostatic processes. Simply, it will most likely turn out to be even better than blarcamesine (Anavex 2-73). Glad to learn that human trials are forthcoming.
From my start with my AVXL holding, I’ve targeted 2023 as the year in which I will determine my investment success. So far, I will hold to it. By 2023, remarkable things will have happened with blarcamesine; most likely it will have gained sales approval somewhere. In 2023, the clinical results with Anavex 3-71 could appear from humans with Alzheimer’s and frontotemporal dementia (FTD). No reason whatsoever to anticipate results will be lacking. Just the opposite; probably far better than even blarcamesine.
https://investorshub.advfn.com/boards/read_ms...=153684550
(2)
(0)
